Global Parasitic Diseases Therapeutic Market
Global Parasitic Diseases Therapeutic Market

Parasitic Diseases Therapeutic Comprehensive Study by Type (Antiprotozoal Therapeutics, Anthelminthic Therapeutics, Scabicides and Pediculicides Therapeutics), Application (Hospitals, Clinics, Homecare settings), Testing Type (Microscopy, Serologic Tests, Molecular Based Assays, Proteomics Testing), Pathogen Type (Protozoa, Ectoparasites, Helminthes) Players and Region - Global Market Outlook to 2025

Parasitic Diseases Therapeutic Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 230 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

The diagnosis and treatment of parasitic diseases have changed significantly due to the increased awareness and technological advances that now allow faster and more accurate diagnosis of parasitic diseases. These advances are crucial for the further diagnosis of these infections, as the quantity and quality of laboratory technicians who are familiar with the classic techniques for examining stool and blood smears for parasites have steadily declined. The majority of laboratories are increasingly relying on non-classical parasitological techniques to accurately diagnose these infections. Prophylactic treatment is designed to prevent the occurrence and spread of parasitic diseases. Preventive chemotherapy is used to control the transmission of helminth infections within a community. Vendors in the market are also developing vaccines to prevent and control chronic diseases, including malaria and other diseases. In addition, researchers are studying physically attenuated parasites in a vaccine to control and prevent diseases such as leishmaniasis donovani and leishmaniasis braziliensi. Therefore, the increasing adoption of prophylactic vaccines for the prevention and control of parasitic diseases will accelerate the growth of the parasitic disease therapeutics market.

The market study is being classified by Type (Antiprotozoal Therapeutics, Anthelminthic Therapeutics and Scabicides and Pediculicides Therapeutics), by Application (Hospitals, Clinics and Homecare settings) and major geographies with country level break-up.

Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc (United Kingdom), Pfizer Inc. (United States) and Sanaria Inc. (United States) are some of the key players profiled in the study.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Parasitic Diseases Therapeutic market by Type, Application and Region.

On the basis of geography, the market of Parasitic Diseases Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Increasing Prevalence of the Parasitic Diseases
  • Increasing Adoption of Prophylactic Treatment

Market Trend
  • The Growing Acceptance of the Vaccines for the Prevention and Control of Parasite Diseases
  • Increasing Expenditure to Boost the Penetration Rate of Treatments of the Parasitic Diseases

Restraints
  • Increased Drug Resistance
  • Side-Effects of the Prescribed Drugs

Opportunities
  • The Rising Initiatives and Programs to Eliminate Parasitic Diseases
  • Increasing Clinical Trial Studies for the Development of New Drugs

Challenges
  • Lack of Effective Therapies





Key Target Audience
Providers of Parasitic Diseases Therapeutic, End-Users, Potential Investors, Market Research Firms, Regulatory Firms and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Antiprotozoal Therapeutics
  • Anthelminthic Therapeutics
  • Scabicides and Pediculicides Therapeutics
By Application
  • Hospitals
  • Clinics
  • Homecare settings
By Testing Type
  • Microscopy
  • Serologic Tests
  • Molecular Based Assays
  • Proteomics Testing

By Pathogen Type
  • Protozoa
  • Ectoparasites
  • Helminthes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Prevalence of the Parasitic Diseases
      • 3.2.2. Increasing Adoption of Prophylactic Treatment
    • 3.3. Market Challenges
      • 3.3.1. Lack of Effective Therapies
    • 3.4. Market Trends
      • 3.4.1. The Growing Acceptance of the Vaccines for the Prevention and Control of Parasite Diseases
      • 3.4.2. Increasing Expenditure to Boost the Penetration Rate of Treatments of the Parasitic Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Parasitic Diseases Therapeutic, by Type, Application, Testing Type, Pathogen Type and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Parasitic Diseases Therapeutic (Value)
      • 5.2.1. Global Parasitic Diseases Therapeutic by: Type (Value)
        • 5.2.1.1. Antiprotozoal Therapeutics
        • 5.2.1.2. Anthelminthic Therapeutics
        • 5.2.1.3. Scabicides and Pediculicides Therapeutics
      • 5.2.2. Global Parasitic Diseases Therapeutic by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Homecare settings
      • 5.2.3. Global Parasitic Diseases Therapeutic by: Testing Type (Value)
        • 5.2.3.1. Microscopy
        • 5.2.3.2. Serologic Tests
        • 5.2.3.3. Molecular Based Assays
        • 5.2.3.4. Proteomics Testing
      • 5.2.4. Global Parasitic Diseases Therapeutic by: Pathogen Type (Value)
        • 5.2.4.1. Protozoa
        • 5.2.4.2. Ectoparasites
        • 5.2.4.3. Helminthes
      • 5.2.5. Global Parasitic Diseases Therapeutic Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Parasitic Diseases Therapeutic (Price)
      • 5.3.1. Global Parasitic Diseases Therapeutic by: Type (Price)
  • 6. Parasitic Diseases Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanaria Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Parasitic Diseases Therapeutic Sale, by Type, Application, Testing Type, Pathogen Type and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Parasitic Diseases Therapeutic (Value)
      • 7.2.1. Global Parasitic Diseases Therapeutic by: Type (Value)
        • 7.2.1.1. Antiprotozoal Therapeutics
        • 7.2.1.2. Anthelminthic Therapeutics
        • 7.2.1.3. Scabicides and Pediculicides Therapeutics
      • 7.2.2. Global Parasitic Diseases Therapeutic by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Homecare settings
      • 7.2.3. Global Parasitic Diseases Therapeutic by: Testing Type (Value)
        • 7.2.3.1. Microscopy
        • 7.2.3.2. Serologic Tests
        • 7.2.3.3. Molecular Based Assays
        • 7.2.3.4. Proteomics Testing
      • 7.2.4. Global Parasitic Diseases Therapeutic by: Pathogen Type (Value)
        • 7.2.4.1. Protozoa
        • 7.2.4.2. Ectoparasites
        • 7.2.4.3. Helminthes
      • 7.2.5. Global Parasitic Diseases Therapeutic Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Parasitic Diseases Therapeutic (Price)
      • 7.3.1. Global Parasitic Diseases Therapeutic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Parasitic Diseases Therapeutic: by Type(USD Million)
  • Table 2. Parasitic Diseases Therapeutic Antiprotozoal Therapeutics , by Region USD Million (2014-2019)
  • Table 3. Parasitic Diseases Therapeutic Anthelminthic Therapeutics , by Region USD Million (2014-2019)
  • Table 4. Parasitic Diseases Therapeutic Scabicides and Pediculicides Therapeutics , by Region USD Million (2014-2019)
  • Table 5. Parasitic Diseases Therapeutic: by Application(USD Million)
  • Table 6. Parasitic Diseases Therapeutic Hospitals , by Region USD Million (2014-2019)
  • Table 7. Parasitic Diseases Therapeutic Clinics , by Region USD Million (2014-2019)
  • Table 8. Parasitic Diseases Therapeutic Homecare settings , by Region USD Million (2014-2019)
  • Table 9. Parasitic Diseases Therapeutic: by Testing Type(USD Million)
  • Table 10. Parasitic Diseases Therapeutic Microscopy , by Region USD Million (2014-2019)
  • Table 11. Parasitic Diseases Therapeutic Serologic Tests , by Region USD Million (2014-2019)
  • Table 12. Parasitic Diseases Therapeutic Molecular Based Assays , by Region USD Million (2014-2019)
  • Table 13. Parasitic Diseases Therapeutic Proteomics Testing , by Region USD Million (2014-2019)
  • Table 14. Parasitic Diseases Therapeutic: by Pathogen Type(USD Million)
  • Table 15. Parasitic Diseases Therapeutic Protozoa , by Region USD Million (2014-2019)
  • Table 16. Parasitic Diseases Therapeutic Ectoparasites , by Region USD Million (2014-2019)
  • Table 17. Parasitic Diseases Therapeutic Helminthes , by Region USD Million (2014-2019)
  • Table 18. South America Parasitic Diseases Therapeutic, by Country USD Million (2014-2019)
  • Table 19. South America Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 20. South America Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 21. South America Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 22. South America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 23. Brazil Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 24. Brazil Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 25. Brazil Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 26. Brazil Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 27. Argentina Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 28. Argentina Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 29. Argentina Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 30. Argentina Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 31. Rest of South America Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 32. Rest of South America Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 33. Rest of South America Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 34. Rest of South America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 35. Asia Pacific Parasitic Diseases Therapeutic, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 37. Asia Pacific Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 38. Asia Pacific Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 39. Asia Pacific Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 40. China Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 41. China Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 42. China Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 43. China Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 44. Japan Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 45. Japan Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 46. Japan Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 47. Japan Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 48. India Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 49. India Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 50. India Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 51. India Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 52. South Korea Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 53. South Korea Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 54. South Korea Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 55. South Korea Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 56. Taiwan Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 57. Taiwan Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 58. Taiwan Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 59. Taiwan Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 60. Australia Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 61. Australia Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 62. Australia Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 63. Australia Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 68. Europe Parasitic Diseases Therapeutic, by Country USD Million (2014-2019)
  • Table 69. Europe Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 70. Europe Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 71. Europe Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 72. Europe Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 73. Germany Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 74. Germany Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 75. Germany Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 76. Germany Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 77. France Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 78. France Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 79. France Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 80. France Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 81. Italy Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 82. Italy Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 83. Italy Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 84. Italy Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 85. United Kingdom Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 86. United Kingdom Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 87. United Kingdom Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 88. United Kingdom Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 89. Netherlands Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 90. Netherlands Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 91. Netherlands Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 92. Netherlands Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 93. Rest of Europe Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 94. Rest of Europe Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 95. Rest of Europe Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 96. Rest of Europe Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 97. MEA Parasitic Diseases Therapeutic, by Country USD Million (2014-2019)
  • Table 98. MEA Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 99. MEA Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 100. MEA Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 101. MEA Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 102. Middle East Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 103. Middle East Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 104. Middle East Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 105. Middle East Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 106. Africa Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 107. Africa Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 108. Africa Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 109. Africa Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 110. North America Parasitic Diseases Therapeutic, by Country USD Million (2014-2019)
  • Table 111. North America Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 112. North America Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 113. North America Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 114. North America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 115. United States Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 116. United States Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 117. United States Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 118. United States Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 119. Canada Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 120. Canada Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 121. Canada Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 122. Canada Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 123. Mexico Parasitic Diseases Therapeutic, by Type USD Million (2014-2019)
  • Table 124. Mexico Parasitic Diseases Therapeutic, by Application USD Million (2014-2019)
  • Table 125. Mexico Parasitic Diseases Therapeutic, by Testing Type USD Million (2014-2019)
  • Table 126. Mexico Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2014-2019)
  • Table 127. Parasitic Diseases Therapeutic: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Parasitic Diseases Therapeutic: by Type(USD Million)
  • Table 134. Parasitic Diseases Therapeutic Antiprotozoal Therapeutics , by Region USD Million (2020-2025)
  • Table 135. Parasitic Diseases Therapeutic Anthelminthic Therapeutics , by Region USD Million (2020-2025)
  • Table 136. Parasitic Diseases Therapeutic Scabicides and Pediculicides Therapeutics , by Region USD Million (2020-2025)
  • Table 137. Parasitic Diseases Therapeutic: by Application(USD Million)
  • Table 138. Parasitic Diseases Therapeutic Hospitals , by Region USD Million (2020-2025)
  • Table 139. Parasitic Diseases Therapeutic Clinics , by Region USD Million (2020-2025)
  • Table 140. Parasitic Diseases Therapeutic Homecare settings , by Region USD Million (2020-2025)
  • Table 141. Parasitic Diseases Therapeutic: by Testing Type(USD Million)
  • Table 142. Parasitic Diseases Therapeutic Microscopy , by Region USD Million (2020-2025)
  • Table 143. Parasitic Diseases Therapeutic Serologic Tests , by Region USD Million (2020-2025)
  • Table 144. Parasitic Diseases Therapeutic Molecular Based Assays , by Region USD Million (2020-2025)
  • Table 145. Parasitic Diseases Therapeutic Proteomics Testing , by Region USD Million (2020-2025)
  • Table 146. Parasitic Diseases Therapeutic: by Pathogen Type(USD Million)
  • Table 147. Parasitic Diseases Therapeutic Protozoa , by Region USD Million (2020-2025)
  • Table 148. Parasitic Diseases Therapeutic Ectoparasites , by Region USD Million (2020-2025)
  • Table 149. Parasitic Diseases Therapeutic Helminthes , by Region USD Million (2020-2025)
  • Table 150. South America Parasitic Diseases Therapeutic, by Country USD Million (2020-2025)
  • Table 151. South America Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 152. South America Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 153. South America Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 154. South America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 155. Brazil Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 156. Brazil Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 157. Brazil Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 158. Brazil Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 159. Argentina Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 160. Argentina Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 161. Argentina Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 162. Argentina Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 163. Rest of South America Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 164. Rest of South America Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 165. Rest of South America Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 166. Rest of South America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 167. Asia Pacific Parasitic Diseases Therapeutic, by Country USD Million (2020-2025)
  • Table 168. Asia Pacific Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 169. Asia Pacific Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 170. Asia Pacific Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 171. Asia Pacific Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 172. China Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 173. China Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 174. China Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 175. China Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 176. Japan Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 177. Japan Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 178. Japan Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 179. Japan Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 180. India Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 181. India Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 182. India Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 183. India Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 184. South Korea Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 185. South Korea Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 186. South Korea Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 187. South Korea Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 188. Taiwan Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 189. Taiwan Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 190. Taiwan Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 191. Taiwan Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 192. Australia Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 193. Australia Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 194. Australia Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 195. Australia Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 196. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 197. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 198. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 199. Rest of Asia-Pacific Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 200. Europe Parasitic Diseases Therapeutic, by Country USD Million (2020-2025)
  • Table 201. Europe Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 202. Europe Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 203. Europe Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 204. Europe Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 205. Germany Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 206. Germany Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 207. Germany Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 208. Germany Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 209. France Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 210. France Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 211. France Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 212. France Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 213. Italy Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 214. Italy Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 215. Italy Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 216. Italy Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 217. United Kingdom Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 218. United Kingdom Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 219. United Kingdom Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 220. United Kingdom Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 221. Netherlands Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 222. Netherlands Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 223. Netherlands Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 224. Netherlands Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 225. Rest of Europe Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 226. Rest of Europe Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 227. Rest of Europe Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 228. Rest of Europe Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 229. MEA Parasitic Diseases Therapeutic, by Country USD Million (2020-2025)
  • Table 230. MEA Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 231. MEA Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 232. MEA Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 233. MEA Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 234. Middle East Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 235. Middle East Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 236. Middle East Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 237. Middle East Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 238. Africa Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 239. Africa Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 240. Africa Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 241. Africa Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 242. North America Parasitic Diseases Therapeutic, by Country USD Million (2020-2025)
  • Table 243. North America Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 244. North America Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 245. North America Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 246. North America Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 247. United States Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 248. United States Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 249. United States Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 250. United States Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 251. Canada Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 252. Canada Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 253. Canada Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 254. Canada Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 255. Mexico Parasitic Diseases Therapeutic, by Type USD Million (2020-2025)
  • Table 256. Mexico Parasitic Diseases Therapeutic, by Application USD Million (2020-2025)
  • Table 257. Mexico Parasitic Diseases Therapeutic, by Testing Type USD Million (2020-2025)
  • Table 258. Mexico Parasitic Diseases Therapeutic, by Pathogen Type USD Million (2020-2025)
  • Table 259. Parasitic Diseases Therapeutic: by Type(USD/Units)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Parasitic Diseases Therapeutic: by Type USD Million (2014-2019)
  • Figure 5. Global Parasitic Diseases Therapeutic: by Application USD Million (2014-2019)
  • Figure 6. Global Parasitic Diseases Therapeutic: by Testing Type USD Million (2014-2019)
  • Figure 7. Global Parasitic Diseases Therapeutic: by Pathogen Type USD Million (2014-2019)
  • Figure 8. South America Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 9. Asia Pacific Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 10. Europe Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 11. MEA Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 12. North America Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 13. Global Parasitic Diseases Therapeutic: by Type USD/Units (2014-2019)
  • Figure 14. Global Parasitic Diseases Therapeutic share by Players 2019 (%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 18. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 24. Sanaria Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Sanaria Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Global Parasitic Diseases Therapeutic: by Type USD Million (2020-2025)
  • Figure 27. Global Parasitic Diseases Therapeutic: by Application USD Million (2020-2025)
  • Figure 28. Global Parasitic Diseases Therapeutic: by Testing Type USD Million (2020-2025)
  • Figure 29. Global Parasitic Diseases Therapeutic: by Pathogen Type USD Million (2020-2025)
  • Figure 30. South America Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 31. Asia Pacific Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 32. Europe Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 33. MEA Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 34. North America Parasitic Diseases Therapeutic Share (%), by Country
  • Figure 35. Global Parasitic Diseases Therapeutic: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Pfizer Inc. (United States)
  • Sanaria Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation